Coherus Oncology (NASDAQ:CHRS) Issues Earnings Results

Coherus Oncology (NASDAQ:CHRS) released its earnings results on Wednesday. The biotechnology company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.05, FiscalAI reports. The firm had revenue of $14.31 million during the quarter, compared to the consensus estimate of $14.41 million. Coherus Oncology had a net margin of 397.30% and a negative return on equity of 198.90%.

Here are the key takeaways from Coherus Oncology’s conference call:

• LOQTORZI sales increased 15% quarter over quarter to $13.6 million, supported by the highest number of new patient starts since launch, lower discontinuations, and gradually improving treatment duration. Management reiterated its 2026 revenue outlook of $57 million to $62 million and expects average quarterly growth of 10% to 15%.
• Tagmokitug studies in head and neck cancer and colorectal cancer, along with the casdozokitug first-line HCC study, have completed enrollment. Early, immature data in PD-1-resistant head and neck cancer showed manageable safety and signs of activity, potentially enriched among HPV-positive patients and those with higher TIRI scores; a formal update is expected in October.
• Casdozokitug HCC data are expected in the fourth quarter, but the study remains relatively immature, with only about half of patients having received three scans. Management said it may not need to wait for overall-survival data to decide on a potential Phase III program, while emphasizing response durability, clinical benefit rate, ctDNA, and IL-27 biomarkers.
• Cash, cash equivalents, and investments declined to $105.3 million from $167 million in the prior quarter, primarily because of $39 million in transition-service-agreement obligations. The company said it remains funded through key 2026–2027 readouts, but the $37.5 million Q2 UDENYCA divestiture milestone was not achieved, subject to final buyer-result adjustments.
• Continuing-operations R&D and SG&A expenses fell year over year, and the company expects full-year 2026 operating expenses of $170 million to $175 million. Legacy biosimilar liabilities also declined substantially and are expected to be largely settled by year-end.

Coherus Oncology Price Performance

CHRS stock traded down $0.07 during mid-day trading on Thursday, reaching $1.38. 511,901 shares of the company traded hands, compared to its average volume of 1,514,784. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.56 and a quick ratio of 1.52. The company has a market capitalization of $212.86 million, a P/E ratio of 0.82 and a beta of 0.98. Coherus Oncology has a 52-week low of $0.81 and a 52-week high of $2.62. The company has a fifty day moving average price of $1.47 and a 200-day moving average price of $1.67.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Guggenheim assumed coverage on Coherus Oncology in a report on Monday, May 11th. They set a “buy” rating and a $12.00 price objective for the company. Weiss Ratings upgraded Coherus Oncology from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 13th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Coherus Oncology has a consensus rating of “Moderate Buy” and an average price target of $8.67.

Hedge Funds Weigh In On Coherus Oncology

A number of large investors have recently modified their holdings of CHRS. Quarry LP bought a new stake in Coherus Oncology during the 3rd quarter worth approximately $26,000. Blair William & Co. IL bought a new position in Coherus Oncology in the 4th quarter valued at $27,000. BNP Paribas Financial Markets grew its position in shares of Coherus Oncology by 108.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 13,832 shares in the last quarter. Corient Private Wealth LLC increased its holdings in shares of Coherus Oncology by 20.0% in the second quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 10,000 shares during the period. Finally, Jane Street Group LLC purchased a new stake in shares of Coherus Oncology in the second quarter worth $46,000. 72.82% of the stock is currently owned by institutional investors.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.